Global Pharmaceutical CDMO Market Growth (Status and Outlook) 2024-2030
Pharmaceutical CDMO, valued at US$ 125.48 billion in 2023, is expected to reach US$ 214.60 billion by 2030, with an 8.0% CAGR driven by increasing demand in the downstream market.
- Bonafide Trust
- 04-01-2024
- Pages : 147
- Figures : 79
- Tables : 202
- Region : Global
- Category : Lifescience
- Healthcare
According to Publisher’s latest study, the global Pharmaceutical CDMO market size was valued at US$ 125480 million in 2023. With the growing demand in the downstream market, the Pharmaceutical CDMO is forecast to a readjusted size of US$ 214600 million by 2030 with a CAGR of 8.0% during the review period.
The research report highlights the growth potential of the global Pharmaceutical CDMO market. Pharmaceutical CDMOs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Pharmaceutical CDMO. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Pharmaceutical CDMO market.
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Contract Pharmaceutical Manufacturing is part of CDMO, which refers to accepting commissions from pharmaceutical companies and providing the service about API production, FDF production, and packaging.
Pharmaceutical companies are likely to outsource a wide range of manufacturing-related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labelling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.
The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical companies are the largest application field, with a market share of more than 60%, followed by biotechnology companies.
Key Features:
The report on the Pharmaceutical CDMO market reflects various aspects and provides valuable insights into the industry.
Market Size and Growth: The research report provides an overview of the current size and growth of the Pharmaceutical CDMO market. It may include historical data, market segmentation by Type (e.g., API CDMO, FDF CDMO), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Pharmaceutical CDMO market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. The pharmaceutical industry's technological developments and medication development and production are handled by the contract development and manufacturing organization. People will require more sophisticated and efficient treatments to heal faster and more effectively as the prevalence of chronic illnesses rises in the community. The market is being driven by the rise in chronic illnesses like cancer. Over the decades, cancer has been the leading cause of mortality. The pharmaceutical, contract development, and manufacturing organization markets will be driven by the growing need for therapeutic advancement and the expanding demand for cancer therapy. In addition, the market for manufacturing organizations and contract development will benefit from the rise in both tailored and generic medications. Healthcare industry technological advancements completed medicine development. The pharmaceutical CDMO market is expected to grow at a faster rate due to factors such as increased research and development spending, more cooperation among the pharmaceutical sectors, and an increase in the elderly population.
It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs. The pharmaceutical sector would receive a smaller profit share because of the outsourcing firm's involvement in the development of medical technology and pharmaceutical medication production. The amount of money invested by the pharmaceutical sector will depend on a variety of elements, including labour force, quantity of purchased orders, and raw supplies. Compared to internal manufacturing, there is a problem with visibility into the manufacturing process in outsourcing production, such as Pharmaceutical CDMO. The pharmaceutical sector would be held accountable for any manufacturing or production flaws carried out by Pharmaceutical CDMO, and the company would suffer a loss to its reputation.
Competitive Landscape: The research report provides an analysis of the competitive landscape within the Pharmaceutical CDMO market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Pharmaceutical CDMO industry. This includes advancements in Pharmaceutical CDMO technology, Pharmaceutical CDMO new entrants, Pharmaceutical CDMO new investments, and other innovations that are shaping the future of Pharmaceutical CDMO.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Pharmaceutical CDMO market. It includes factors influencing customers' purchasing decisions, and preferences for Pharmaceutical CDMO products.
Government Policies and Incentives: The research report analyses the impact of government policies and incentives on the Pharmaceutical CDMO market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting the Pharmaceutical CDMO market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assesses the environmental impact and sustainability aspects of the Pharmaceutical CDMO market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provides market forecasts and outlook for the Pharmaceutical CDMO industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: Innovative operational technologies are carried out by pharmaceutical contract development and manufacturing organizations, or CDMOs. Future expansion prospects in the contract development and manufacturing organization market will be brought about by the rise in the need for generic and precision pharmaceuticals. Throughout the forecast period, technological developments like the implementation of artificial intelligence, blockchain, cloud computing, and machine learning are anticipated to present profitable prospects for market expansion.
The report concludes with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Pharmaceutical CDMO market.
Recent developments- A new sterile injectables CDMO called NovaCina was introduced in April 2023 by The Bridgewest Group, a multinational private investment firm that works with life science software and contract development and manufacturing organizations. The product is developed by NovaCina into a fully functional commercial product.
In January 2023, Vector Biomed secured $15 million in funding to launch as a business providing CDMO services. The startup wants to close the gap in the supply of gene and cell therapy producers with the money it has raised.
Medipost announced in October 2022 the opening of a new CDMO business to provide products for gene and cell therapy in the Korean market. By introducing these services, Medipost hopes to become a one-stop shop for the creation of medicines and biopharmaceuticals.
Market Segmentation:
The pharmaceutical CDMO market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
1. Segmentation by type
• API CDMO
• FDF CDMO
• Packaging CDMO
• Clinical CDMO
2. Segmentation by application
• Pharmaceutical Company
• Biotechnology Company
• Other
This report also splits the market by region: Asia-Pacific is likely to increase at a high rate over the projection period, and it currently holds the largest market share for manufacturing firms' contract development. The rising population in nations like China and India is blamed for the expansion of the pharmaceutical CDMO business in the area. This region's growing population means there is a greater need for cutting-edge, dependable medical facilities. The Asia-Pacific region's contract development and manufacturing organization market is growing as a result of favourable government laws, cheaper labour costs, and declining manufacturing industry costs. The Asia-Pacific region's dominance in the pharmaceutical CDMO market will be sustained by the rising demand for customized and generic medications in these areas.
The greatest market for pharmaceutical CDMO services is also found in America. The growth of the pharmaceutical industries' manufacturing facilities is anticipated to provide a boost to the area. This region's growing senior population would increase demand for these services from the healthcare sector. The pharmaceutical industry's increasing technical innovation will fuel the growth of the contract development and manufacturing organization markets. Furthermore, the expansion of the American healthcare market is supported by a well-established healthcare infrastructure and supportive government policies aimed at enhancing healthcare services. Throughout the projection period, Europe's pharmaceutical CDMO market is anticipated to rise noticeably. France, the United Kingdom, and Germany are anticipated to contribute the most to the expansion of the European market. With increased investment in the pharmaceutical industry for improved healthcare, the region is anticipated to develop.
3. Americas
• United States
• Canada
• Mexico
• Brazil
4. APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
5. Europe
• Germany
• France
• UK
• Italy
• Russia
6. Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
• Lonza
• Catalent
• Thermo Fisher Scientific
• Samsung Biologics
• Fareva
• WuXi AppTech
• WuXi Biologics
• Siegfried
• FUJIFILM Diosynth Biotechnologies
• Asymchem
• Pfizer CentreOne
• Delpharm
• Recipharm
• AGC Pharma Chemicals
• Boehringer Ingelheim
• Vetter
• Curia
• Aenova
• Porton
• Piramal
• Strides Pharma
• NextPharma
• Famar
• Jubilant
• Alcami
• Euroapi
• Eurofins
• Avid Bioservices
• BioVectra
• CPL
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download Sample
Table of Contents
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Pharmaceutical CDMO Market Size 2019-2030
- 2.1.2 Pharmaceutical CDMO Market Size CAGR by Region 2019 VS 2023 VS 2030
- 2.2 Pharmaceutical CDMO Segment by Type
- 2.2.1 API CDMO
- 2.2.2 FDF CDMO
- 2.2.3 Packaging CDMO
- 2.2.4 Clinical CDMO
- 2.3 Pharmaceutical CDMO Market Size by Type
- 2.3.1 Pharmaceutical CDMO Market Size CAGR by Type (2019 VS 2023 VS 2030)
- 2.3.2 Global Pharmaceutical CDMO Market Size Market Share by Type (2019-2024)
- 2.4 Pharmaceutical CDMO Segment by Application
- 2.4.1 Pharmaceutical Company
- 2.4.2 Biotechnology Company
- 2.4.3 Other
- 2.5 Pharmaceutical CDMO Market Size by Application
- 2.5.1 Pharmaceutical CDMO Market Size CAGR by Application (2019 VS 2023 VS 2030)
- 2.5.2 Global Pharmaceutical CDMO Market Size Market Share by Application (2019-2024)
- 3 Pharmaceutical CDMO Market Size by Player
- 3.1 Pharmaceutical CDMO Market Size Market Share by Players
- 3.1.1 Global Pharmaceutical CDMO Revenue by Players (2019-2024)
- 3.1.2 Global Pharmaceutical CDMO Revenue Market Share by Players (2019-2024)
- 3.2 Global Pharmaceutical CDMO Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
- 4 Pharmaceutical CDMO by Regions
- 4.1 Pharmaceutical CDMO Market Size by Regions (2019-2024)
- 4.2 Americas Pharmaceutical CDMO Market Size Growth (2019-2024)
- 4.3 APAC Pharmaceutical CDMO Market Size Growth (2019-2024)
- 4.4 Europe Pharmaceutical CDMO Market Size Growth (2019-2024)
- 4.5 Middle East & Africa Pharmaceutical CDMO Market Size Growth (2019-2024)
- 5 Americas
- 5.1 Americas Pharmaceutical CDMO Market Size by Country (2019-2024)
- 5.2 Americas Pharmaceutical CDMO Market Size by Type (2019-2024)
- 5.3 Americas Pharmaceutical CDMO Market Size by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Pharmaceutical CDMO Market Size by Region (2019-2024)
- 6.2 APAC Pharmaceutical CDMO Market Size by Type (2019-2024)
- 6.3 APAC Pharmaceutical CDMO Market Size by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 7 Europe
- 7.1 Europe Pharmaceutical CDMO by Country (2019-2024)
- 7.2 Europe Pharmaceutical CDMO Market Size by Type (2019-2024)
- 7.3 Europe Pharmaceutical CDMO Market Size by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Pharmaceutical CDMO by Region (2019-2024)
- 8.2 Middle East & Africa Pharmaceutical CDMO Market Size by Type (2019-2024)
- 8.3 Middle East & Africa Pharmaceutical CDMO Market Size by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Global Pharmaceutical CDMO Market Forecast
- 10.1 Global Pharmaceutical CDMO Forecast by Regions (2025-2030)
- 10.1.1 Global Pharmaceutical CDMO Forecast by Regions (2025-2030)
- 10.1.2 Americas Pharmaceutical CDMO Forecast
- 10.1.3 APAC Pharmaceutical CDMO Forecast
- 10.1.4 Europe Pharmaceutical CDMO Forecast
- 10.1.5 Middle East & Africa Pharmaceutical CDMO Forecast
- 10.2 Americas Pharmaceutical CDMO Forecast by Country (2025-2030)
- 10.2.1 United States Pharmaceutical CDMO Market Forecast
- 10.2.2 Canada Pharmaceutical CDMO Market Forecast
- 10.2.3 Mexico Pharmaceutical CDMO Market Forecast
- 10.2.4 Brazil Pharmaceutical CDMO Market Forecast
- 10.3 APAC Pharmaceutical CDMO Forecast by Region (2025-2030)
- 10.3.1 China Pharmaceutical CDMO Market Forecast
- 10.3.2 Japan Pharmaceutical CDMO Market Forecast
- 10.3.3 Korea Pharmaceutical CDMO Market Forecast
- 10.3.4 Southeast Asia Pharmaceutical CDMO Market Forecast
- 10.3.5 India Pharmaceutical CDMO Market Forecast
- 10.3.6 Australia Pharmaceutical CDMO Market Forecast
- 10.4 Europe Pharmaceutical CDMO Forecast by Country (2025-2030)
- 10.4.1 Germany Pharmaceutical CDMO Market Forecast
- 10.4.2 France Pharmaceutical CDMO Market Forecast
- 10.4.3 UK Pharmaceutical CDMO Market Forecast
- 10.4.4 Italy Pharmaceutical CDMO Market Forecast
- 10.4.5 Russia Pharmaceutical CDMO Market Forecast
- 10.5 Middle East & Africa Pharmaceutical CDMO Forecast by Region (2025-2030)
- 10.5.1 Egypt Pharmaceutical CDMO Market Forecast
- 10.5.2 South Africa Pharmaceutical CDMO Market Forecast
- 10.5.3 Israel Pharmaceutical CDMO Market Forecast
- 10.5.4 Turkey Pharmaceutical CDMO Market Forecast
- 10.5.5 GCC Countries Pharmaceutical CDMO Market Forecast
- 10.6 Global Pharmaceutical CDMO Forecast by Type (2025-2030)
- 10.7 Global Pharmaceutical CDMO Forecast by Application (2025-2030)
- 11 Key Players Analysis
- 11.1 Lonza
- 11.1.1 Lonza Company Information
- 11.1.2 Lonza Pharmaceutical CDMO Product Offered
- 11.1.3 Lonza Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.1.4 Lonza Main Business Overview
- 11.1.5 Lonza Latest Developments
- 11.2 Catalent
- 11.2.1 Catalent Company Information
- 11.2.2 Catalent Pharmaceutical CDMO Product Offered
- 11.2.3 Catalent Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.2.4 Catalent Main Business Overview
- 11.2.5 Catalent Latest Developments
- 11.3 Thermo Fisher Scientific
- 11.3.1 Thermo Fisher Scientific Company Information
- 11.3.2 Thermo Fisher Scientific Pharmaceutical CDMO Product Offered
- 11.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.3.4 Thermo Fisher Scientific Main Business Overview
- 11.3.5 Thermo Fisher Scientific Latest Developments
- 11.4 Samsung Biologics
- 11.4.1 Samsung Biologics Company Information
- 11.4.2 Samsung Biologics Pharmaceutical CDMO Product Offered
- 11.4.3 Samsung Biologics Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.4.4 Samsung Biologics Main Business Overview
- 11.4.5 Samsung Biologics Latest Developments
- 11.5 Fareva
- 11.5.1 Fareva Company Information
- 11.5.2 Fareva Pharmaceutical CDMO Product Offered
- 11.5.3 Fareva Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.5.4 Fareva Main Business Overview
- 11.5.5 Fareva Latest Developments
- 11.6 WuXi AppTech
- 11.6.1 WuXi AppTech Company Information
- 11.6.2 WuXi AppTech Pharmaceutical CDMO Product Offered
- 11.6.3 WuXi AppTech Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.6.4 WuXi AppTech Main Business Overview
- 11.6.5 WuXi AppTech Latest Developments
- 11.7 WuXi Biologics
- 11.7.1 WuXi Biologics Company Information
- 11.7.2 WuXi Biologics Pharmaceutical CDMO Product Offered
- 11.7.3 WuXi Biologics Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.7.4 WuXi Biologics Main Business Overview
- 11.7.5 WuXi Biologics Latest Developments
- 11.8 Siegfried
- 11.8.1 Siegfried Company Information
- 11.8.2 Siegfried Pharmaceutical CDMO Product Offered
- 11.8.3 Siegfried Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.8.4 Siegfried Main Business Overview
- 11.8.5 Siegfried Latest Developments
- 11.9 FUJIFILM Diosynth Biotechnologies
- 11.9.1 FUJIFILM Diosynth Biotechnologies Company Information
- 11.9.2 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Product Offered
- 11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.9.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
- 11.9.5 FUJIFILM Diosynth Biotechnologies Latest Developments
- 11.10 Asymchem
- 11.10.1 Asymchem Company Information
- 11.10.2 Asymchem Pharmaceutical CDMO Product Offered
- 11.10.3 Asymchem Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.10.4 Asymchem Main Business Overview
- 11.10.5 Asymchem Latest Developments
- 11.11 Pfizer CentreOne
- 11.11.1 Pfizer CentreOne Company Information
- 11.11.2 Pfizer CentreOne Pharmaceutical CDMO Product Offered
- 11.11.3 Pfizer CentreOne Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.11.4 Pfizer CentreOne Main Business Overview
- 11.11.5 Pfizer CentreOne Latest Developments
- 11.12 Delpharm
- 11.12.1 Delpharm Company Information
- 11.12.2 Delpharm Pharmaceutical CDMO Product Offered
- 11.12.3 Delpharm Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.12.4 Delpharm Main Business Overview
- 11.12.5 Delpharm Latest Developments
- 11.13 Recipharm
- 11.13.1 Recipharm Company Information
- 11.13.2 Recipharm Pharmaceutical CDMO Product Offered
- 11.13.3 Recipharm Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.13.4 Recipharm Main Business Overview
- 11.13.5 Recipharm Latest Developments
- 11.14 AGC Pharma Chemicals
- 11.14.1 AGC Pharma Chemicals Company Information
- 11.14.2 AGC Pharma Chemicals Pharmaceutical CDMO Product Offered
- 11.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.14.4 AGC Pharma Chemicals Main Business Overview
- 11.14.5 AGC Pharma Chemicals Latest Developments
- 11.15 Boehringer Ingelheim
- 11.15.1 Boehringer Ingelheim Company Information
- 11.15.2 Boehringer Ingelheim Pharmaceutical CDMO Product Offered
- 11.15.3 Boehringer Ingelheim Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.15.4 Boehringer Ingelheim Main Business Overview
- 11.15.5 Boehringer Ingelheim Latest Developments
- 11.16 Vetter
- 11.16.1 Vetter Company Information
- 11.16.2 Vetter Pharmaceutical CDMO Product Offered
- 11.16.3 Vetter Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.16.4 Vetter Main Business Overview
- 11.16.5 Vetter Latest Developments
- 11.17 Curia
- 11.17.1 Curia Company Information
- 11.17.2 Curia Pharmaceutical CDMO Product Offered
- 11.17.3 Curia Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.17.4 Curia Main Business Overview
- 11.17.5 Curia Latest Developments
- 11.18 Aenova
- 11.18.1 Aenova Company Information
- 11.18.2 Aenova Pharmaceutical CDMO Product Offered
- 11.18.3 Aenova Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.18.4 Aenova Main Business Overview
- 11.18.5 Aenova Latest Developments
- 11.19 Porton
- 11.19.1 Porton Company Information
- 11.19.2 Porton Pharmaceutical CDMO Product Offered
- 11.19.3 Porton Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.19.4 Porton Main Business Overview
- 11.19.5 Porton Latest Developments
- 11.20 Piramal
- 11.20.1 Piramal Company Information
- 11.20.2 Piramal Pharmaceutical CDMO Product Offered
- 11.20.3 Piramal Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.20.4 Piramal Main Business Overview
- 11.20.5 Piramal Latest Developments
- 11.21 Strides Pharma
- 11.21.1 Strides Pharma Company Information
- 11.21.2 Strides Pharma Pharmaceutical CDMO Product Offered
- 11.21.3 Strides Pharma Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.21.4 Strides Pharma Main Business Overview
- 11.21.5 Strides Pharma Latest Developments
- 11.22 NextPharma
- 11.22.1 NextPharma Company Information
- 11.22.2 NextPharma Pharmaceutical CDMO Product Offered
- 11.22.3 NextPharma Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.22.4 NextPharma Main Business Overview
- 11.22.5 NextPharma Latest Developments
- 11.23 Famar
- 11.23.1 Famar Company Information
- 11.23.2 Famar Pharmaceutical CDMO Product Offered
- 11.23.3 Famar Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.23.4 Famar Main Business Overview
- 11.23.5 Famar Latest Developments
- 11.24 Jubilant
- 11.24.1 Jubilant Company Information
- 11.24.2 Jubilant Pharmaceutical CDMO Product Offered
- 11.24.3 Jubilant Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.24.4 Jubilant Main Business Overview
- 11.24.5 Jubilant Latest Developments
- 11.25 Alcami
- 11.25.1 Alcami Company Information
- 11.25.2 Alcami Pharmaceutical CDMO Product Offered
- 11.25.3 Alcami Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.25.4 Alcami Main Business Overview
- 11.25.5 Alcami Latest Developments
- 11.26 Euroapi
- 11.26.1 Euroapi Company Information
- 11.26.2 Euroapi Pharmaceutical CDMO Product Offered
- 11.26.3 Euroapi Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.26.4 Euroapi Main Business Overview
- 11.26.5 Euroapi Latest Developments
- 11.27 Eurofins
- 11.27.1 Eurofins Company Information
- 11.27.2 Eurofins Pharmaceutical CDMO Product Offered
- 11.27.3 Eurofins Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.27.4 Eurofins Main Business Overview
- 11.27.5 Eurofins Latest Developments
- 11.28 Avid Bioservices
- 11.28.1 Avid Bioservices Company Information
- 11.28.2 Avid Bioservices Pharmaceutical CDMO Product Offered
- 11.28.3 Avid Bioservices Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.28.4 Avid Bioservices Main Business Overview
- 11.28.5 Avid Bioservices Latest Developments
- 11.29 BioVectra
- 11.29.1 BioVectra Company Information
- 11.29.2 BioVectra Pharmaceutical CDMO Product Offered
- 11.29.3 BioVectra Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.29.4 BioVectra Main Business Overview
- 11.29.5 BioVectra Latest Developments
- 11.30 CPL
- 11.30.1 CPL Company Information
- 11.30.2 CPL Pharmaceutical CDMO Product Offered
- 11.30.3 CPL Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2019-2024)
- 11.30.4 CPL Main Business Overview
- 11.30.5 CPL Latest Developments
- 12 Research Findings and Conclusion
Table 1. Pharmaceutical CDMO Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of API CDMO
Table 3. Major Players of FDF CDMO
Table 4. Major Players of Packaging CDMO
Table 5. Major Players of Clinical CDMO
Table 6. Pharmaceutical CDMO Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 7. Global Pharmaceutical CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 8. Global Pharmaceutical CDMO Market Size Market Share by Type (2019-2024)
Table 9. Pharmaceutical CDMO Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 10. Global Pharmaceutical CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 11. Global Pharmaceutical CDMO Market Size Market Share by Application (2019-2024)
Table 12. Global Pharmaceutical CDMO Revenue by Players (2019-2024) & ($ Millions)
Table 13. Global Pharmaceutical CDMO Revenue Market Share by Player (2019-2024)
Table 14. Pharmaceutical CDMO Key Players Head office and Products Offered
Table 15. Pharmaceutical CDMO Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Pharmaceutical CDMO Market Size by Regions 2019-2024 & ($ Millions)
Table 19. Global Pharmaceutical CDMO Market Size Market Share by Regions (2019-2024)
Table 20. Global Pharmaceutical CDMO Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Pharmaceutical CDMO Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Pharmaceutical CDMO Market Size by Country (2019-2024) & ($ Millions)
Table 23. Americas Pharmaceutical CDMO Market Size Market Share by Country (2019-2024)
Table 24. Americas Pharmaceutical CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 25. Americas Pharmaceutical CDMO Market Size Market Share by Type (2019-2024)
Table 26. Americas Pharmaceutical CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 27. Americas Pharmaceutical CDMO Market Size Market Share by Application (2019-2024)
Table 28. APAC Pharmaceutical CDMO Market Size by Region (2019-2024) & ($ Millions)
Table 29. APAC Pharmaceutical CDMO Market Size Market Share by Region (2019-2024)
Table 30. APAC Pharmaceutical CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 31. APAC Pharmaceutical CDMO Market Size Market Share by Type (2019-2024)
Table 32. APAC Pharmaceutical CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 33. APAC Pharmaceutical CDMO Market Size Market Share by Application (2019-2024)
Table 34. Europe Pharmaceutical CDMO Market Size by Country (2019-2024) & ($ Millions)
Table 35. Europe Pharmaceutical CDMO Market Size Market Share by Country (2019-2024)
Table 36. Europe Pharmaceutical CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 37. Europe Pharmaceutical CDMO Market Size Market Share by Type (2019-2024)
Table 38. Europe Pharmaceutical CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 39. Europe Pharmaceutical CDMO Market Size Market Share by Application (2019-2024)
Table 40. Middle East & Africa Pharmaceutical CDMO Market Size by Region (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Pharmaceutical CDMO Market Size Market Share by Region (2019-2024)
Table 42. Middle East & Africa Pharmaceutical CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Pharmaceutical CDMO Market Size Market Share by Type (2019-2024)
Table 44. Middle East & Africa Pharmaceutical CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 45. Middle East & Africa Pharmaceutical CDMO Market Size Market Share by Application (2019-2024)
Table 46. Key Market Drivers & Growth Opportunities of Pharmaceutical CDMO
Table 47. Key Market Challenges & Risks of Pharmaceutical CDMO
Table 48. Key Industry Trends of Pharmaceutical CDMO
Table 49. Global Pharmaceutical CDMO Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 50. Global Pharmaceutical CDMO Market Size Market Share Forecast by Regions (2025-2030)
Table 51. Global Pharmaceutical CDMO Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 52. Global Pharmaceutical CDMO Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 53. Lonza Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 54. Lonza Pharmaceutical CDMO Product Offered
Table 55. Lonza Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 56. Lonza Main Business
Table 57. Lonza Latest Developments
Table 58. Catalent Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 59. Catalent Pharmaceutical CDMO Product Offered
Table 60. Catalent Main Business
Table 61. Catalent Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 62. Catalent Latest Developments
Table 63. Thermo Fisher Scientific Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 64. Thermo Fisher Scientific Pharmaceutical CDMO Product Offered
Table 65. Thermo Fisher Scientific Main Business
Table 66. Thermo Fisher Scientific Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 67. Thermo Fisher Scientific Latest Developments
Table 68. Samsung Biologics Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 69. Samsung Biologics Pharmaceutical CDMO Product Offered
Table 70. Samsung Biologics Main Business
Table 71. Samsung Biologics Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 72. Samsung Biologics Latest Developments
Table 73. Fareva Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 74. Fareva Pharmaceutical CDMO Product Offered
Table 75. Fareva Main Business
Table 76. Fareva Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 77. Fareva Latest Developments
Table 78. WuXi AppTech Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 79. WuXi AppTech Pharmaceutical CDMO Product Offered
Table 80. WuXi AppTech Main Business
Table 81. WuXi AppTech Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 82. WuXi AppTech Latest Developments
Table 83. WuXi Biologics Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 84. WuXi Biologics Pharmaceutical CDMO Product Offered
Table 85. WuXi Biologics Main Business
Table 86. WuXi Biologics Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 87. WuXi Biologics Latest Developments
Table 88. Siegfried Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 89. Siegfried Pharmaceutical CDMO Product Offered
Table 90. Siegfried Main Business
Table 91. Siegfried Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 92. Siegfried Latest Developments
Table 93. FUJIFILM Diosynth Biotechnologies Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 94. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Product Offered
Table 95. FUJIFILM Diosynth Biotechnologies Main Business
Table 96. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 97. FUJIFILM Diosynth Biotechnologies Latest Developments
Table 98. Asymchem Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 99. Asymchem Pharmaceutical CDMO Product Offered
Table 100. Asymchem Main Business
Table 101. Asymchem Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 102. Asymchem Latest Developments
Table 103. Pfizer CentreOne Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 104. Pfizer CentreOne Pharmaceutical CDMO Product Offered
Table 105. Pfizer CentreOne Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 106. Pfizer CentreOne Main Business
Table 107. Pfizer CentreOne Latest Developments
Table 108. Delpharm Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 109. Delpharm Pharmaceutical CDMO Product Offered
Table 110. Delpharm Main Business
Table 111. Delpharm Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 112. Delpharm Latest Developments
Table 113. Recipharm Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 114. Recipharm Pharmaceutical CDMO Product Offered
Table 115. Recipharm Main Business
Table 116. Recipharm Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 117. Recipharm Latest Developments
Table 118. AGC Pharma Chemicals Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 119. AGC Pharma Chemicals Pharmaceutical CDMO Product Offered
Table 120. AGC Pharma Chemicals Main Business
Table 121. AGC Pharma Chemicals Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 122. AGC Pharma Chemicals Latest Developments
Table 123. Boehringer Ingelheim Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 124. Boehringer Ingelheim Pharmaceutical CDMO Product Offered
Table 125. Boehringer Ingelheim Main Business
Table 126. Boehringer Ingelheim Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 127. Boehringer Ingelheim Latest Developments
Table 128. Vetter Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 129. Vetter Pharmaceutical CDMO Product Offered
Table 130. Vetter Main Business
Table 131. Vetter Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 132. Vetter Latest Developments
Table 133. Curia Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 134. Curia Pharmaceutical CDMO Product Offered
Table 135. Curia Main Business
Table 136. Curia Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 137. Curia Latest Developments
Table 138. Aenova Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 139. Aenova Pharmaceutical CDMO Product Offered
Table 140. Aenova Main Business
Table 141. Aenova Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 142. Aenova Latest Developments
Table 143. Porton Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 144. Porton Pharmaceutical CDMO Product Offered
Table 145. Porton Main Business
Table 146. Porton Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 147. Porton Latest Developments
Table 148. Piramal Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 149. Piramal Pharmaceutical CDMO Product Offered
Table 150. Piramal Main Business
Table 151. Piramal Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 152. Piramal Latest Developments
Table 153. Strides Pharma Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 154. Strides Pharma Pharmaceutical CDMO Product Offered
Table 155. Strides Pharma Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 156. Strides Pharma Main Business
Table 157. Strides Pharma Latest Developments
Table 158. NextPharma Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 159. NextPharma Pharmaceutical CDMO Product Offered
Table 160. NextPharma Main Business
Table 161. NextPharma Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 162. NextPharma Latest Developments
Table 163. Famar Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 164. Famar Pharmaceutical CDMO Product Offered
Table 165. Famar Main Business
Table 166. Famar Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 167. Famar Latest Developments
Table 168. Jubilant Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 169. Jubilant Pharmaceutical CDMO Product Offered
Table 170. Jubilant Main Business
Table 171. Jubilant Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 172. Jubilant Latest Developments
Table 173. Alcami Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 174. Alcami Pharmaceutical CDMO Product Offered
Table 175. Alcami Main Business
Table 176. Alcami Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 177. Alcami Latest Developments
Table 178. Euroapi Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 179. Euroapi Pharmaceutical CDMO Product Offered
Table 180. Euroapi Main Business
Table 181. Euroapi Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 182. Euroapi Latest Developments
Table 183. Eurofins Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 184. Eurofins Pharmaceutical CDMO Product Offered
Table 185. Eurofins Main Business
Table 186. Eurofins Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 187. Eurofins Latest Developments
Table 188. Avid Bioservices Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 189. Avid Bioservices Pharmaceutical CDMO Product Offered
Table 190. Avid Bioservices Main Business
Table 191. Avid Bioservices Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 192. Avid Bioservices Latest Developments
Table 193. BioVectra Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 194. BioVectra Pharmaceutical CDMO Product Offered
Table 195. BioVectra Main Business
Table 196. BioVectra Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 197. BioVectra Latest Developments
Table 198. CPL Details, Company Type, Pharmaceutical CDMO Area Served and Its Competitors
Table 199. CPL Pharmaceutical CDMO Product Offered
Table 200. CPL Main Business
Table 201. CPL Pharmaceutical CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 202. CPL Latest Developments
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. Read More
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. Read More
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. Read More
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). Read More
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization.png "Nikita Jabrela")
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (21 March, 2025)
- Notify To Team (21 March, 2025)
- Report updation (22 March, 2025)
- Report Quality Check (22 March, 2025)
- Report Dispatch (23 March, 2025)
- Hard Copy
Recently Viewed Products
Global Pharmaceutical CDMO Market Growth (Status and Outlook) 2024-2030
We are friendly and approachable, give us a call.